Correspondence
Intractable erosive lichen planus treated successfully with rituximab
K. Heelan,
K. Heelan
Department of Dermatology, South Infirmary-Victoria University Hospital, Cork, Ireland
Search for more papers by this author M.A. McAleer,
M.A. McAleer
Department of Dermatology, South Infirmary-Victoria University Hospital, Cork, Ireland
Search for more papers by this author L. Roche,
L. Roche
Department of Dermatology, South Infirmary-Victoria University Hospital, Cork, Ireland
Search for more papers by this author C. McCreary,
C. McCreary
Cork University Dental School and Hospital, Wilton, Cork, Ireland
Search for more papers by this author M. Murphy,
M. Murphy
Department of Dermatology, South Infirmary-Victoria University Hospital, Cork, Ireland
Search for more papers by this author
K. Heelan,
K. Heelan
Department of Dermatology, South Infirmary-Victoria University Hospital, Cork, Ireland
Search for more papers by this author M.A. McAleer,
M.A. McAleer
Department of Dermatology, South Infirmary-Victoria University Hospital, Cork, Ireland
Search for more papers by this author L. Roche,
L. Roche
Department of Dermatology, South Infirmary-Victoria University Hospital, Cork, Ireland
Search for more papers by this author C. McCreary,
C. McCreary
Cork University Dental School and Hospital, Wilton, Cork, Ireland
Search for more papers by this author M. Murphy,
M. Murphy
Department of Dermatology, South Infirmary-Victoria University Hospital, Cork, Ireland
Search for more papers by this author
First published: 17 December 2014
No abstract is available for this article.
References
- 1Parmentier L, Bron BA, Prins C et al. Mucocutaneous lichen planus with esophageal involvement: successful treatment with an anti-CD20 monoclonal antibody. Arch Dermatol 2008; 144: 1427–30.
- 2Lavanya N, Jayanthi P, Rao UK, Ranganathan K. Oral lichen planus: an update on pathogenesis and treatment. J Oral Maxillofac Pathol 2011; 15: 127–32.
- 3O'Neill ID, Scully C. Biologics in oral medicine: ulcerative disorders. Oral Dis 2013; 19: 37–45.
- 4Gurcan HM, Keskin DB, Stern JN et al. A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol 2009; 9: 10–25.
- 5Heelan K, Al-Mohammedi F, Smith MJ et al. Durable remission of pemphigus with a fixed-dose rituximab protocol. JAMA Dermatol 2014; 150: 703–8.
- 6Heelan K, Walsh S, Shear NH. Treatment of mucous membrane pemphigoid with rituximab. J Am Acad Dermatol 2013; 69: 310–11.
- 7Gregoriou S, Koutsoukou XA, Panayotides I et al. Pemphigus vulgaris of the epiglottis successfully treated with rituximab. J Eur Acad Dermatol Venereol 2014; DOI: 10.1111/jdv.12536.
- 8Melet J, Mulleman D, Goupille P et al. Rituximab-induced T cell depletion in patients with rheumatoid arthritis: association with clinical response. Arthritis Rheum 2013; 65: 2783–90.
- 9Schmidt E, Hunzelmann N, Zillikens D et al. Rituximab in refractory autoimmune bullous diseases. Clin Exp Dermatol 2006; 31: 503–8.
- 10Colliou N, Picard D, Caillot F et al. Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response. Sci Transl Med 2013; 5: 175ra30.
